Jeffrey B. Mirviss
Net Worth

Last updated:

What is Jeffrey B. Mirviss net worth?

The estimated net worth of Mr. Jeffrey B. Mirviss is at least $22,592,405 as of 29 May 2024. He owns shares worth $2,912,607 as insider, has earned $14,425,358 from insider trading and has received compensation worth at least $5,254,440 in Boston Scientific Corporation.

What is the salary of Jeffrey B. Mirviss?

Mr. Jeffrey B. Mirviss salary is $875,740 per year as Executive Vice President & Pres of Peripheral Interventions in Boston Scientific Corporation.

How old is Jeffrey B. Mirviss?

Mr. Jeffrey B. Mirviss is 59 years old, born in 1966.

What stocks does Jeffrey B. Mirviss currently own?

As insider, Mr. Jeffrey B. Mirviss owns shares in one company:

Company Title Shares Price per share Total value
Boston Scientific Corporation (BSX) Executive Vice President & Pres of Peripheral Interventions 28,022 $103.94 $2,912,607

What does Boston Scientific Corporation do?

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX logo
BSX
Boston Scientific Corporation
$103.94

Jeffrey B. Mirviss insider trading

Boston Scientific Corporation

Mr. Jeffrey B. Mirviss has made 26 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 63,802 units of BSX stock worth $4,791,466 on 29 May 2024.

The largest trade he's ever made was exercising 63,802 units of BSX stock on 29 May 2024. As of 29 May 2024 he still owns at least 28,022 units of BSX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 63,802 $75.1 $4,791,466
Option
Common Stock 33,726 $17.26 $582,111
Option
Stock Option (Right to Buy) 33,726 $17.26 $582,111
Sale
Common Stock 14,506 $66.45 $963,924
Sale
Common Stock 4,960 $66.35 $329,096
Option
Deferred Stock Units 2,817 N/A N/A
Option
Common Stock 2,817 N/A N/A
Option
Restricted Stock Units 3,333 N/A N/A
Option
Common Stock 3,333 N/A N/A
Option
Restricted Stock Units 2,970 N/A N/A
Option
Common Stock 2,970 N/A N/A
Sale
Common Stock 30,344 $59.25 $1,797,882
Option
Common Stock 30,344 $16.31 $494,911
Option
Stock Option (Right to Buy) 30,344 $16.31 $494,911
Sale
Common Stock 15,000 $58.4 $876,000
Option
Stock Option (Right to Buy) 15,000 $16.31 $244,650
Option
Common Stock 15,000 $16.31 $244,650
Sale
Common Stock 11,931 $57.82 $689,862
Option
Common Stock 17,439 N/A N/A
Option
Performance Share Units 17,439 N/A N/A
Sale
Common Stock 353 $55.03 $19,426
Option
Common Stock 649 N/A N/A
Option
Deferred Stock Units 649 N/A N/A
Sale
Common Stock 4,657 $54.5 $253,811
Sale
Common Stock 13,971 $53.14 $742,419
Sale
Common Stock 4,903 $50.4 $247,111
Sale
Common Stock 4,903 $49.6 $243,189
Sale
Common Stock 3,340 $46.1 $153,974
Sale
Common Stock 2,313 $46.32 $107,138
Option
Common Stock 2,804 N/A N/A
Option
Deferred Stock Units 2,804 N/A N/A
Option
Deferred Stock Units 2,817 N/A N/A
Option
Common Stock 2,817 N/A N/A
Sale
Common Stock 2,061 $46.35 $95,527
Option
Restricted Stock Units 3,333 N/A N/A
Option
Common Stock 3,333 N/A N/A
Option
Restricted Stock Units 2,970 N/A N/A
Sale
Common Stock 1,409 $46.79 $65,927
Option
Common Stock 2,970 N/A N/A
Sale
Common Stock 11,236 $44.5 $500,002
Option
Common Stock 2,037 N/A N/A
Option
Deferred Stock Units 2,037 N/A N/A
Option
Common Stock 2,804 N/A N/A
Option
Deferred Stock Units 2,804 N/A N/A
Option
Common Stock 2,816 N/A N/A
Option
Restricted Stock Units 3,333 N/A N/A
Option
Deferred Stock Units 2,816 N/A N/A
Option
Common Stock 3,333 N/A N/A
Option
Deferred Stock Units 2,030 N/A N/A
Option
Common Stock 2,030 N/A N/A
Sale
Common Stock 6,840 $43.54 $297,807
Option
Common Stock 10,105 N/A N/A
Option
Performance Share Units 10,105 N/A N/A
Option
Common Stock 649 N/A N/A
Option
Deferred Stock Units 649 N/A N/A
Sale
Common Stock 6,748 $45.22 $305,145
Sale
Common Stock 48,439 N/A N/A
Option
Common Stock 48,439 N/A N/A
Option
Stock Option (Right to Buy) 48,439 N/A N/A
Sale
Common Stock 28,123 $6.28 $176,612
Option
Common Stock 28,123 $6.28 $176,612
Option
Stock Option (Right to Buy) 28,123 $6.28 $176,612
Option
Deferred Stock Units 2,037 N/A N/A
Option
Common Stock 2,037 N/A N/A
Option
Common Stock 2,318 N/A N/A
Option
Deferred Stock Units 2,318 N/A N/A
Option
Deferred Stock Units 2,804 N/A N/A
Option
Common Stock 2,804 N/A N/A
Option
Common Stock 2,816 N/A N/A
Option
Deferred Stock Units 2,816 N/A N/A
Option
Deferred Stock Units 2,030 N/A N/A
Option
Common Stock 2,030 N/A N/A
Sale
Common Stock 5,494 $38.75 $212,893
Sale
Common Stock 8,108 $35.32 $286,334
Option
Performance Share Units 11,967 N/A N/A
Option
Common Stock 11,967 N/A N/A
Option
Deferred Stock Units 649 N/A N/A
Option
Common Stock 649 N/A N/A
Option
Common Stock 46,584 $7.16 $333,541
Option
Stock Option (Right to Buy) 46,584 $7.16 $333,541
Sale
Common Stock 46,584 $7.16 $333,541
Sale
Common Stock 9,139 $42.31 $386,671
Option
Common Stock 60,000 $6.31 $378,600
Option
Stock Option (Right to Buy) 60,000 $6.31 $378,600
Sale
Common Stock 60,000 $6.31 $378,600
Option
Common Stock 2,037 N/A N/A
Option
Deferred Stock Units 2,037 N/A N/A
Option
Deferred Stock Units 2,146 N/A N/A
Option
Common Stock 2,146 N/A N/A
Option
Common Stock 2,318 N/A N/A
Option
Deferred Stock Units 2,318 N/A N/A
Option
Deferred Stock Units 2,804 N/A N/A
Option
Common Stock 2,804 N/A N/A
Option
Common Stock 2,030 N/A N/A
Option
Deferred Stock Units 2,030 N/A N/A
Option
Common Stock 23,077 $7.41 $171,001
Option
Stock Option (Right to Buy) 23,077 $7.41 $171,001
Sale
Common Stock 23,077 $7.41 $171,001
Option
Common Stock 9,939 N/A N/A
Option
Performance Share Units 9,939 N/A N/A
Option
Deferred Stock Units 649 N/A N/A
Option
Common Stock 649 N/A N/A
Option
Deferred Stock Units 2,036 N/A N/A

Boston Scientific key executives

Boston Scientific Corporation executives and other stock owners filed with the SEC: